Search

Corporate Sponsor Program

View the EHA Ranking 2025

"Alone we can do so little; together we can do so much.

Read more

How to apply for an EHA Innovation Grant

On this page, we explain all of the actions you'll need to take when submitting an EHA Innovation Grant application.

Read more

EHA-SWG Scientific Meeting on MDS/MPN/AML: Commonalities and Differences of Myeloid Neoplasms

Join us for this unique and rare opportunity and exchange ideas with MDS, MPN, and AML experts in one meeting. Internationally renowned experts will provide presentations and share the recent developments and answers to your clinical questions.

Read more

Key messages of the 22nd Congress of EHA brought to the Middle East and North Africa

The second edition of the Highlights of Past EHA (HOPE) brought the key messages of the 22nd Congress of EHA to the Cairo, Egypt in September 2017.

Read more

Trial membership

Are you interested in connecting with EHA and our vibrant community, but you're not yet ready to apply for membership?

By becoming an EHA guest, you can enjoy 60 days of free access to:

The European Hematology Curriculum
Select courses on EHA Campus
You'll…

Read more

EHA-EMN Joint Session at the European Myeloma Network Meeting EMN2023

On Saturday, 22 April, EHA and EMN brought together patients, regulators and clinicians to discuss Novel Endpoints in Multiple Myeloma.

Read more

The European Union must deliver funding for research of blood disorders

At the 20th Annual Congress of EHA, the results of two major projects are presented. The first is a study into the Cost of Blood Disorders in the EU Member States and Norway, Iceland, and Switzerland.

Read more

EHA Awards 2011 at the 16th Congress of EHA in London

Bob Löwenberg will be the fourth recipient of the Jean Bernard Lifetime Achievement Award which was presented for the first time at the 13th Annual Congress in Copenhagen.

Read more

EHA-ECL led statement calls for protection of the Hospital Exemption

The hospital exemption (HE) is a vital provision within the EU's pharmaceutical legislation, currently subject to a revision.

Read more